Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB2 days ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB15 hours ago · The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease, commonly...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB2 days ago · In July 2024, Regeneron and Sanofi announced the European Commission approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six,...
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB1 day ago · With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant …
WEBSep 11, 2024 · Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown …
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease. If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union .
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB2 days ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of what is already one of the industry’s best-selling medicines.